https://www.selleckchem.com/pr....oducts/cbl0137-cbl-0
A significantly lower clinical score was recorded in DES than in CTR (p less then 0.01) at D90 and D180 (p less then 0.01). After 180 days of treatment (D18, a significant reduction of mean levels of IFAT was observed in the DES group (p = 0.03). A highly significant reduction of testosterone (p = 0.01) was observed in the DES group during the study. No statistical correlation between clinical scores, IFAT titres and testosterone within two groups was observed. Data suggested that the agonist of GnRH may be useful in the trea
Beğen
Yorum Yap
Paylaş
